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Abstract
The use of nucleic acid, DNA and RNA, based strategies to disrupt gene expression as a 
therapeutic is quickly emerging. Indeed, synthetic oligonucleotides represent a major component 
of emerging gene therapeutics. However, the efficiency and specificity of intracellular uptake for 
non-modified oligonucleotides is rather poor. Utilizing RNA based oligonucleotides as 
therapeutics is even more challenging to deliver, due to extremely fast enzymatic degradation of 
the RNAs. Like unmodified oligonucleotides, RNAs also get rapidly degraded in vivo and 
demonstrate large off-target binding events when they can reach and enter the desired target cells. 
One approach that holds much promise is the utilization of “click chemistry” to conjugate receptor 
or cell specific targeting molecules directly to the effector oligonucleotides. We discuss here the 
applications of the breakthrough technology of CuAAC “click-chemistry” and the immense 
potential in utilizing “click chemistry” in the development of new age targeted oligonucleotide 
therapeutics.
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1. Introduction
Gene therapy is an emerging approach that targets intracellular nucleic acids, those DNA 
and RNAs, associated with human diseases. Synthetic oligonucleotides represent a major 
type of currently used gene therapeutics. However, the efficiency and specificity of 
intracellular uptake for non-modified oligonucleotides is poor, with the vast majority 
trafficking directly to the liver1. Utilizing RNA therapeutics are even more challenging to 
deliver, due to extremely fast enzymatic degradation of the RNAs. Like unmodified 
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oligonucleotides, RNAs also get rapidly degraded in vivo and show large off-target binding 
even when they can reach and enter the desired target cells.
Clearly, creating a successful gene therapeutic is not limited to ensuring a successful base-
pairing of a therapeutic to its target, but also ensuring stability and cell target specificity. 
Finding a suitable delivery carrier and enhancing the target specificity for gene therapeutics 
are both crucial key components required to advance oligonucleotide and RNA based 
therapeutics to a clinically relevant setting. Indeed, currently stability and receptor or cell 
targeting effectors can be added to both oligonucleotides and RNAs by conjugation with 
other biomolecules. Recent successful examples include oligonucleotide-lipid, 
oligonucleotide-carbohydrate and oligonucleotide-peptide conjugates (reviewed in2). An 
alternative to direct conjugations is the use of nanoparticles to shuttle therapeutic 
oligonucleotides with (in)organic polymers, small molecules and other biomolecules. The 
advantage of nanoassemblies is their relatively simple preparation compared to 
bioconjugation. However, nanoparticles formed by non-covalent interactions between 
molecules may inevitably prove to be unstable and require very fast delivery options, which 
are not available to date (reviewed in3).
Charged, chemically complex and sensitive biomolecules put limitations on the chemistry 
applied to link them. Click chemistry refers to a broad group of methods unified by the 
general concept of simple, biology-friendly and bioorthogonal procedures that conjugate 
molecules in a specific fashion. A breakthrough in click chemistry has been the development 
of copper-catalyzed click chemistry, CuAAC, by Sharpless, Finn et al. (2002). Rapidly after 
the discovery of CuAAC click-chemistry, the method was extended to the copper-free 
approach strain promoted click chemistry, or SPAAC, Diels-Alder, thiol-Michael click 
reactions. Today, several classical organic reactions have been modified to a “click” version. 
Each has its advantages and disadvantages and some can even be performed directly in live 
cells. With regards to gene therapy, CuAAC and SPAAC play a key role in creating 
decorated therapeutic DNA, RNA and their synthetic analogues, most of which have to date 
been evaluated in vitro (Figure 1). This is mainly due to the simplicity of the procedure, 
broad accessibility of the reagents and simple work up. However, new methods allow for the 
attachment of different modifications to one gene therapeutic, which potentially could be 
beneficial for in vivo applications. Indeed, a method to directly conjugate cell receptor 
targeted proteins, aptamers etc., to oligonucleotides or therapeutic RNAs could revolutionize 
oligonucleotide therapeutics.
Here in honor of one of the founders of “click chemistry”, Professor M.G. Finn’s 60th 
birthday, we review the current applications of click chemistry, CuAAC in particular the 
generation of new oligonucleotides and their nanoassemblies as therapeutic modalities.
2. Emerging targets in gene therapy and use of synthetic biomolecules
Therapeutic oligonucleotide strategies are promising owing to the fact they are designed a 
priori to be specific towards their target, with minimal off-target effects4. As such, targeting 
a single gene or RNA species with an oligonucleotide is thought to be a more effective 
approach in various diseases where drug approaches have shown reduced or limited efficacy. 
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However, limitations in delivering these molecules to the host, as well as identifying their 
distribution and target efficiency into target cells in a multicellular environment, have 
hampered the progression of these strategies into the clinic. Click chemistry provides a 
promising approach to generate oligonucleotides that can be delivered into target cells safely 
and with a high efficiency. Current strategies are in their infancy and have to date been 
mainly proof-of-concept. Most research to date focuses on different delivery strategies and 
visualization strategies of oligonucleotides being delivered into their cellular targets.
Recent studies have used click-chemistry to mediate the construction of nanoparticles that 
are loaded with their oligonucleotide cargo for efficient delivery into cells5–6. O’Brien et al., 
developed a new method called “SnapFect” using a nucleic acid complex with a bio-
orthogonal group and a modified cell surface to recognize and deliver the oligonucleotide 
complex into the cell7. This strategy had minimal toxicity, few steps, was highly efficient 
and is compatible with siRNA, CRISPR and microfluidic technology. The authors also 
found that this method is amendable to work in stem and primary cells. Other authors have 
developed moieties that may help to control gene silencing in vivo. Harun et al., developed 
siRNA molecules conjugated to a poly(N-isoproprylacylamide) moiety that behaves as a 
coil-globule that changes its conformation with heat, with an optimal conformation at 
35 °C8. The conformation results in accessibility of the siRNA to the RNA induced silencing 
complex. The authors tested the thermo-responsive siRNA conjugate and found that they 
were able to induce gene silencing at higher temperatures8.
Immunotherapy is a promising strategy in cancer therapy, and has shown recent success with 
the use of oncolytic viruses and CAR-T cell therapies. However, these strategies are 
expensive. As such, the use of other chemical adjuvants, such as cytokines, small 
oligonucleotides, or cancer antigens may be a more cost effective approach, despite their 
limited success to date.9 One innovative approach recently developed cell lines to express 
chemically modified glycan carrying azide moieties, which subsequently allowed the cells to 
be clicked with different adjuvants, including ODNs. These cells were found to be able to 
stimulate macrophages in vitro, and when injected into mice, resulted in significantly 
smaller tumor sizes, than the control cells. Additionally, when mice were re-challenged with 
unmodified cells, no new tumors developed, suggesting broad protection from immune 
system targeting of the tumor9.
Click chemistry approaches have been developed and effectively used to conjugate 
fluorescent molecules, 5’ caps, lipids, polysaccharides and peptides to RNA molecules10. 
Further, “click chemistry” has been developed as a strategy to circularize RNA10. Others 
have found using ”click chemistry” that bio-conjugating mRNA with different polyamines at 
the 5’cap, increased formation of poly-ion complexes (PICs) and their binding to initiation 
factor 4E to increase translational efficiency of the mRNA target in vitro11. These 
technologies may help to better understand gene regulation and result in the development of 
smarter strategies that have discreet and specific effects on their intended targets, by 
visualizing where these siRNA conjugates are delivered to in vivo and by using the most 
relevant moieties to obtain the best siRNA conjugates to effectively deliver and target the 
appropriate cells for treatment. Other uses of click-chemistry have been to develop better 
labelling of RNA in vitro and in vivo to better profile RNA populations in distinct cellular 
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populations.12–13 Furthermore, click chemistry has also been shown to be an effective tool to 
analyze the transport of stem cells to different locations14–15 and has been used to 
understand the molecular dynamics and potential heterogeneity in drug activity in vivo16.
While progressive steps have been made in creating better deliverable molecules for gene 
therapy, few studies have been focused on a specific disease using an RNA-conjugate to 
mediate a positive medical outcome. The current strategies suggest that using the tool-box 
that click-chemistry affords, creating or redeveloping old strategies with new moieties for 
better delivery, enhanced uptake, and increased specificity into target cells, may result in 
new pathways for gene therapy. Indeed, research by our group(s) has focused largely on the 
use of peptide moieties that have shown to have great potential in overcoming the cell 
membrane to deliver its siRNA cargo to effect gene silencing for both HIV17 and cholesterol 
regulation18.
3. Growing role of click chemistry in the development of gene therapeutics
Since the first reports on click chemistry for gene therapeutics,19–20 the original CuAAC 
approach has been extended by alternative chemical strategies. Wiessler et al., explored the 
Diels Alder click chemistry for therapeutic peptide nucleic acids (PNA; Figure 2)21. Several 
groups have demonstrated that PNA conjugates created by click chemistry have 
advantageous delivery properties compared to unconjugated precursors. In one body of 
work, Pipkort et al., applied a similar approach to Diels Alder click, for cell-specific 
fluorescence imaging using PNA probes.22 Using modular PNA probes allowed for the 
combination of the imaging and therapeutic activities in one PNA molecule. The mRNA 
product of the cysteine protease cathepsin B (CtsB) gene was imaged and simultaneously 
degraded using the peptide-PNA conjugate. The degradation was completed by adding a 
cleavage site to the CtsB complementary PNA probe. Further, Wojciechowska et al., used 
click chemistry to make cell penetrating peptide (CPP) attached to PNA for atherosclerosis 
treatment, although the affinity to target hSTAT1 mRNA was demonstrated only in vitro23. 
The toxicity of PNA has been reported by several groups24–25, however it is not commented 
on in the aforementioned PNA click papers.
For therapeutic applications, there is a need for purification from any residual copper that 
can be left in the product of the CuAAC reaction. This is particularly important when cell 
penetrating and other peptides are clicked, due to the high affinity of amino acids to 
copper27–28. One approach is the use of Tangential flow filtration (TFF) purification that 
yields hundreds of grams of clicked biomolecules without any sign of toxicity in cells or in 
vivo29. Another strategy is using a copper-free click reaction. Wang et al., used SPAACto 
modify DNA with diverse functionalities30. SPAAC has advantages of high reaction rate at 
ultramild conditions when the two molecules to be reacted have no steric hindrance. 
However, the rate of SPAAC can be lower compared to CuAAC when clicking longer 
peptides (> 20 amino acids) to oligonucleotides31.
Phosphorodiamidite morpholino oligonucleotides (PMO) conjugated with cell-penetrating 
peptides exhibit a high potential for application as therapeutics for Duchenne muscular 
dystrophy32. Conjugates were initially screened using a selection of peptide conjugates 
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(SELPEPCON) procedure and then the best hits were tested in cells. The SELPEPCON 
procedure is beneficial for the selection of bioactive peptides that suggest the possibility of 
crossing the blood-brain barrier through the conjugates and simultaneously being time and 
cost effective for therapeutic screening32.
Since the late 2000s, most studies on click chemistry for gene therapy have used 
nanomaterials, being beneficial for the delivery and activity of gene therapeutics. Ghosh and 
Hamilton developed thermosensitive dendrimers based on G-quadruplex forming CG rich 
sequences33. They used different metal ion concentrations to drive the assembly which was 
confirmed by imaging. DNA-microcapsules prepared by Cavaleri et al. contained the 
hydrophobic core built from a poly N-isopropylacrylamide (PNIPAM) polymer and reactive 
“click” domains34. The products were decorated with DNA and poly ethylene glycol (PEG) 
and showed higher stability that the analogues that did not contain the PNIPAM hydrophobic 
core (Figure 3A).
Clicking cargos for gene therapeutics is another recent approach. Alshaer et al., 
functionalized liposomes with an anti-CD44 aptamer via a thiol-maleimide click reaction, 
for selective targeting of cancer cells – Fig. 3 B)35. Uptake was proven in two CD44(+) 
human cancer cell lines, lung cancer A549 and breast cancer MDA-MB-231. A new 
cyclodextrin derivative CD-PLLD, consisting of a beta-cyclodextrin core and poly-L-lysine 
dendron, efficiently delivered siRNA encoding plasmid to cancer HNE-1 cells36. 
Simultaneously, a docetaxel was delivered. This star-shaped copolymer of cyclodextrin 
showed high activity, better blood compatibility and also lower cytotoxicity compared to the 
controls. It is exciting that clicked modified cyclodextrins have also been found to be 
capable of siRNA delivery to neurons37. Furthermore, low toxicity and high stability in 
serum has been confirmed for these vectors.
As to the specificity, additional modifications such as LNA are helpful to decrease off-target 
binding27. Decorating DNA with several peptide units resulted in improved stability and 
target recognition specificity of antisense oligonucleotides that target BRAF V600E 
oncogene. The CuAAC method gave good yields of double-labelled products as well. A 
“clickable” LNA variant has been suggested for miRNA targeting within LNA/DNA 
probes38. Besides often-applied sugar modification and terminal attachment by click 
chemistry, nucleobases can be modified by click chemistry as well. This is often applied 
when using clickable triphosphates (TPPs), due to better yields upon enzymatic 
incorporation than for sugar-modified TPPs. Also, the modification can be done post-
synthetically with a broad range of azides. Xiong et al., applied 8-aza-7-deazaguanine 
oligonucleotides to create branched Y-shaped DNA39. Annealing of branched DNA with 
complementary oligonucleotides yielded well defined nanostructures. Selective target 
recognition was also confirmed by in vitro assays.
In the last decade, focus has shifted from DNA to RNA therapeutics. As for DNA and its 
analogues, chemical modifications are compulsory for RNA therapeutics to increase stability 
in vivo and to ensure the specific delivery and intracellular uptake. Recent studies show that 
conjugation of therapeutic siRNA with fatty acids and carbohydrate residues benefit the 
therapeutic performance of RNA (RNA-galnac and RNA-fa papers40–42). For these 
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molecules, maleimide and N-Hydroxysuccinimide (NHS) chemistry is being used. Most 
methods are developed for DNA conjugation and do not meet the additional requirement of 
mild conditions needed for RNA modification. Growing applications in RNA therapy 
stimulate rapid development of bioconjugation methods that allow RNA labelling in high 
yields and purity43–44(Figure 5).
4. Comparison of “clicked” gene therapeutics to alternatives
Although much progress has been made on the click chemistry of therapeutic 
oligonucleotides and their delivery vesicles, critical points that need to be addressed are their 
potential toxicity and possibility to scale-up production. TFF purification, which has been 
mentioned previously, is a good way to scale up the CuAAC reaction29. Moreover, as has 
been described by Jones et al., click modification can affect the uptake pathway for 
therapeutics30. Trafficking determines the fate of a therapeutic inside the cell. Therefore, 
tracking studies are crucial to get structure-activity relationships for conjugates. Lastly, 
reducing the price of gene therapy is of crucial importance48.
The performance of available clicked therapeutics vs. alternative therapies is summarized in 
Table 1. Recently, Costales et al., compared clicked small molecule drugs with 
oligonucleotides49. They showed that morpholino-oligonucleotides had superior specificity 
in vivo when targeting myotonic dystrophy type 2 (DM2) associated gene alterations. 
Especially, therapeutic poly-oligonucleotides assembled on site had superior activity when 
compared to small molecule drugs. In addition, conjugation with CPPs was found to 
dramatically enhance the therapeutic performance of PMOs used to target exon skipping in 
the mouse mdx model50.
Multidrug resistance is an issue that blocks the use of available small molecule drugs49. It 
was shown that using siRNA and ULANAR PS antisense/siRNA makes cancer cells more 
permeable and reduces resistance. Wu et al., proposed a novel copolymer decorated with 
folic acid and siRNA for breast cancer treatment51. Co-delivery with doxorubicin resulted in 
suppression of tumor growth while maintaining rather low toxicity on other tissues. In 
another work was reported that multidrug resistance could be reversed using click polymer/
iMDR1-pDNA complex nanoparticles56. This approach could become useful in breast 
cancer and other solid tumor treatments in cases when conventional therapy is not working 
and to reduce the toxicity.
Macrophages could be targeted by siRNA via click mannosylated polymeric micelles52. 
Being involved in cancer and atherosclerosis pathology, macrophages represent an important 
therapeutic target. CD206 (mannose receptor) is primarily expressed on macrophages which 
ensured specific delivery of mannose-decorated siRNA micelles. Up to a 13-fold higher 
siRNA concentration was found in the macrophages compared to CD206 negative control 
cells which supports the high specificity of the approach. The authors underline that this 
approach is general and can be adopted for click functionalization with other target ligands 
to direct siRNA delivery52.
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Main competitors to gene therapeutics remain small molecule drugs53. Small molecules 
have the advantage of well controlled chemical composition and low cost. However, many of 
them suffer from poor water solubility and high toxicity. Additionally, cells often become 
resistant to small molecule drugs, via mutagenesis57. It is worth noting that the therapeutic 
action of these drugs can be improved by click chemistry as well53–54. The drugs can be 
used in mixed formulations with siRNA,51 or they can be covalently conjugated to 
antibodies and nucleic acids including aptamers55.
Lastly, the synthesis of biodegradable polymers is an exciting approach that could solve the 
issue of drug clearance from the blood stream. Zhao et al., prepared disulfide - containing 
copolymers and showed that they are useful for gene delivery58.
5. Conclusions
In summary, click chemistry finds a growing amount of applications in the development of 
gene therapeutics and is now being applied for direct oligonucleotide modification, cargo 
functionalization or the preparation of nucleotide variants at the nucleoside level. Click 
chemistry on DNA is relatively well established, whereas RNA modification by click 
chemistry requires further improvements. The sensitivity of unmodified RNA to chemical 
reagents and enzymes puts a high demand on the conditions for modifications.
Among prepared molecules, peptide-oligonucleotide conjugates and oligonucleotide 
nanomaterials show the best therapeutic performance. It is exciting that observations to date 
suggest gene therapeutics can reverse drug resistance from virus and solid tumors. Delivery 
and intracellular uptake remain the rate-limiting step, but this issue plagues all therapeutic 
developments. However, it is convincing from recent developments described in this review 
that these two issues can be successfully overcome using appropriate design and conjugation 
strategies.
Compared with small molecule drugs, the high cost of synthetic oligonucleotides and 
peptides is another obstacle for gene therapy application. Nevertheless, given the rapid 
development in oligonucleotide and peptide syntheses and the low cost of click chemistry 
reagents, the overall therapeutic price is bound to fall as the field progresses.
Recent discoveries in RNA biology also provide new targets for clicked therapeutics. 
Examples are miRNA and lncRNA59–62. Following the development of new clickable 
nucleosides, nucleotides and oligonucleotide modification reagents, targeting regulatory 
RNAs is an exciting new direction that might bring new advances to the field of synthetic 
gene therapeutics.
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Figure 1. 
Main principles of click chemistry (A), applications of “clicked” diagnostic tools, 
therapeutics and nanomaterials (B). FG1-2 = functional groups that are specific for 
bioconjugation and unreactive with other biological groups. L = linker.
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Figure 2. 
Chemical structures of PNA (1), morpholino (2); Diels Alder (a)26, reverse electron-demand 
Diels-Alder (b) and SPAAC (c) for oligonucleotide-peptide conjugation.
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Figure 3. 
Oligonucleotide nanomaterials as gene therapeutics. Functionalization of DNA-Polymer (A) 
microcapsules;34 and (B) Liposomes functionalized with CD44 Aptamer35.
Astakhova et al. Page 14
Mol Pharm. Author manuscript; available in PMC 2018 August 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Specific recognition of BRAF RNA by internally clicked peptide-oligonucleotide conjugates 
(POCs)27
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Figure 5. 
Approaches of “clicked” therapeutic RNA. siRNA conjugate with lipophilic molecule on a 
solid CPG support A);45 Biotinylated siRNA conjugated with streptavidin activated 
monoclonal antibody B);46 Thiol-reactive siRNA conjugated with reduced Fab fragment 
C)47.
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